Efficiency of tocilizumab therapy for an exacerbation of systemic lupus erythematosus: A case report and a review of literature
Interleukin-6 (IL-6) is one of the major proinflammatory cytokines, which, by interacting with hepatocytes, induces the synthesis of a broad spectrum of acute phase inflammatory proteins. IL-6 plays an important role in the development and progression of systemic lupus erythematosus (SLE), participa...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2017-09-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/780 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849339371325489152 |
|---|---|
| author | S. K. Solovyev A. A. Mesnyankina D. E. Karateev E. L. Luchikhina Ya. A. Sigidin E. A. Aseeva A. V. Elonakov E. L. Nasonov |
| author_facet | S. K. Solovyev A. A. Mesnyankina D. E. Karateev E. L. Luchikhina Ya. A. Sigidin E. A. Aseeva A. V. Elonakov E. L. Nasonov |
| author_sort | S. K. Solovyev |
| collection | DOAJ |
| description | Interleukin-6 (IL-6) is one of the major proinflammatory cytokines, which, by interacting with hepatocytes, induces the synthesis of a broad spectrum of acute phase inflammatory proteins. IL-6 plays an important role in the development and progression of systemic lupus erythematosus (SLE), participates in the differentiation of CD4/CD8 regulatory T lymphocytes and in the production of autoantibodies by B lymphocytes, and increases the survival of plasmablasts. Tocilizumab (TCZ) is a humanized anti-IL-6 receptor antibody that neutralizes the pleiotropic effects of the cytokine. The use of this drug in SLE can have acceptable efficiency with the high inflammatory activity that is accompanied by fever, polyarthritis, polyserositis, skin lesions, and hemolytic anemia. The authors demonstrated the successful use of TCZ in a female patient with a documented diagnosis of SLE with a high activity (SLEDAI-2K-11). The use of the drug was justified by the prevalence of musculoarticular, constitutional (fever) disease, a high immunological activity (anti-DNA antibodies, 150 IU/ml; antinuclear factor, 1/1280 h; CRP, 88). This therapy could achieve complete relief of fever at day 2 after the first infusion of TCZ, a reduction, and subsequently complete relief of arthritis and normalization of laboratory blood parameters. TCZ has a satisfactory safety profile and may be considered as an alternative treatment for SLE when glucocorticoids, cytostatic agents, and rituximab are ineffective. |
| format | Article |
| id | doaj-art-cadb67e109a6409180587f4166e7e57c |
| institution | Kabale University |
| issn | 1996-7012 2310-158X |
| language | Russian |
| publishDate | 2017-09-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj-art-cadb67e109a6409180587f4166e7e57c2025-08-20T03:44:09ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2017-09-01113859010.14412/1996-7012-2017-3-85-902053Efficiency of tocilizumab therapy for an exacerbation of systemic lupus erythematosus: A case report and a review of literatureS. K. Solovyev0A. A. Mesnyankina1D. E. Karateev2E. L. Luchikhina3Ya. A. Sigidin4E. A. Aseeva5A. V. Elonakov6E. L. Nasonov7V.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyMoscow Regional Research and Clinical InstituteV.A. Nasonova Research Institute of RheumatologyInterleukin-6 (IL-6) is one of the major proinflammatory cytokines, which, by interacting with hepatocytes, induces the synthesis of a broad spectrum of acute phase inflammatory proteins. IL-6 plays an important role in the development and progression of systemic lupus erythematosus (SLE), participates in the differentiation of CD4/CD8 regulatory T lymphocytes and in the production of autoantibodies by B lymphocytes, and increases the survival of plasmablasts. Tocilizumab (TCZ) is a humanized anti-IL-6 receptor antibody that neutralizes the pleiotropic effects of the cytokine. The use of this drug in SLE can have acceptable efficiency with the high inflammatory activity that is accompanied by fever, polyarthritis, polyserositis, skin lesions, and hemolytic anemia. The authors demonstrated the successful use of TCZ in a female patient with a documented diagnosis of SLE with a high activity (SLEDAI-2K-11). The use of the drug was justified by the prevalence of musculoarticular, constitutional (fever) disease, a high immunological activity (anti-DNA antibodies, 150 IU/ml; antinuclear factor, 1/1280 h; CRP, 88). This therapy could achieve complete relief of fever at day 2 after the first infusion of TCZ, a reduction, and subsequently complete relief of arthritis and normalization of laboratory blood parameters. TCZ has a satisfactory safety profile and may be considered as an alternative treatment for SLE when glucocorticoids, cytostatic agents, and rituximab are ineffective.https://mrj.ima-press.net/mrj/article/view/780systemic lupus erythematosustocilizumabinterleukin-6therapy |
| spellingShingle | S. K. Solovyev A. A. Mesnyankina D. E. Karateev E. L. Luchikhina Ya. A. Sigidin E. A. Aseeva A. V. Elonakov E. L. Nasonov Efficiency of tocilizumab therapy for an exacerbation of systemic lupus erythematosus: A case report and a review of literature Современная ревматология systemic lupus erythematosus tocilizumab interleukin-6 therapy |
| title | Efficiency of tocilizumab therapy for an exacerbation of systemic lupus erythematosus: A case report and a review of literature |
| title_full | Efficiency of tocilizumab therapy for an exacerbation of systemic lupus erythematosus: A case report and a review of literature |
| title_fullStr | Efficiency of tocilizumab therapy for an exacerbation of systemic lupus erythematosus: A case report and a review of literature |
| title_full_unstemmed | Efficiency of tocilizumab therapy for an exacerbation of systemic lupus erythematosus: A case report and a review of literature |
| title_short | Efficiency of tocilizumab therapy for an exacerbation of systemic lupus erythematosus: A case report and a review of literature |
| title_sort | efficiency of tocilizumab therapy for an exacerbation of systemic lupus erythematosus a case report and a review of literature |
| topic | systemic lupus erythematosus tocilizumab interleukin-6 therapy |
| url | https://mrj.ima-press.net/mrj/article/view/780 |
| work_keys_str_mv | AT sksolovyev efficiencyoftocilizumabtherapyforanexacerbationofsystemiclupuserythematosusacasereportandareviewofliterature AT aamesnyankina efficiencyoftocilizumabtherapyforanexacerbationofsystemiclupuserythematosusacasereportandareviewofliterature AT dekarateev efficiencyoftocilizumabtherapyforanexacerbationofsystemiclupuserythematosusacasereportandareviewofliterature AT elluchikhina efficiencyoftocilizumabtherapyforanexacerbationofsystemiclupuserythematosusacasereportandareviewofliterature AT yaasigidin efficiencyoftocilizumabtherapyforanexacerbationofsystemiclupuserythematosusacasereportandareviewofliterature AT eaaseeva efficiencyoftocilizumabtherapyforanexacerbationofsystemiclupuserythematosusacasereportandareviewofliterature AT avelonakov efficiencyoftocilizumabtherapyforanexacerbationofsystemiclupuserythematosusacasereportandareviewofliterature AT elnasonov efficiencyoftocilizumabtherapyforanexacerbationofsystemiclupuserythematosusacasereportandareviewofliterature |